Skip 
Navigation Link
Medical Disorders
Resources
Basic InformationLookupsLatest News
Sound Progress Made Toward Global Containment of PoliovirusGene Sequencing May Reveal Risks for Rare DiseasesHigher Fish Intake Appears to Reduce RA SymptomsReview Spotlights Optimal Care of T2DM + OsteoporosisAcne-Related Depression, Anxiety Not Tied to Oxidative StressStudy Challenges Touted Link Between Eczema and Heart DiseaseImmunizations for High Flyin' TravelersCarpal Tunnel Up With Increased Electronic Device UseGuided Approach to Exercise May Help Chronic Fatigue PatientsFamily History Questionnaire Ups Genetic Counseling for CRCBlood Test Can Detect GLUT1 Deficiency SyndromeWallpaper May Breed Toxins: StudyFish Eaters Report Less Rheumatoid Arthritis PainGuided Exercise May Help Chronic Fatigue Patients: Study2006 to 2013 Saw Increase in ER Use for Herpes ZosterNearly 60 Percent With Conjunctivitis Fill Antibiotic RxTissue Testing Can Spot Zika at Birth: CDCGuidelines Address Peri-Op Care in Rheumatic DiseaseZika-Bearing Mosquitoes More Widespread in U.S. Than ExpectedMarital Status Among Factors Tied to Gout Rx AdherenceMany Chronic Illnesses Linked to Suicide RiskVaccine Curbs High Cholesterol in MiceStudy Hints at Link Between Some Statins, Parkinson's RiskHydrotherapy Plus Conventional Drugs Beneficial in RAChronic Lyme Disease Treatments Tied to Serious Adverse EffectsOlder Age Needn't Be a Barrier to Herniated Disc SurgeryNon-Opioid Drug More Effective for Migraines: StudyHealth Tip: Managing Arthritis FatigueCertain Criteria May Be Better Than Others in RA Assessment20 Percent of Hospital Patients Have Side Effects From Abx RxRecreational Activity-Linked Facial Fractures Up in SeniorsUnusual Measles Outbreak Described in Ontario in Early 2015Seniors Get Good Results From Herniated Disc Surgery'Good' Donor Bacteria Can Last Long Term in Stool Transplant PatientsNovel Retinal Lesion Seen in Some Ebola SurvivorsHealth Tip: Recognizing Summer Allergy SymptomsAre You at Risk for Metabolic Syndrome?Antiplatelet Bleeding Risk Higher Than Expected for Older PatientsVideo Call May Be as Good as Doctor Visit for HeadacheCould Prefab Blood Vessels Revolutionize Root Canals?A Sufferer's Guide to Easin' Sneezin' SeasonHospitals Get Good News About Fighting Staph InfectionsCases of Legionnaires' Disease Reported in NYC, Las VegasOlive Oil, Ibuprofen May Have Synergistic EffectsObesity Prevalence Has Doubled in More Than 70 CountriesSeveral New Medications in the Pipeline to Prevent MigraineReview: Depression Screening As Inpatient Important, FeasibleVitamin B6 Linked to Increased Risk of Hip Fracture2 Billion Worldwide Are Obese or OverweightPatient's Education Level May Be Key to Heart Risk
Questions and AnswersLinksBook Reviews
Related Topics

Non-Opioid Drug More Effective for Migraines: Study

HealthDay News
by -- Robert Preidt
Updated: Jun 19th 2017

new article illustration

MONDAY, June 19, 2017 (HealthDay News) -- The drug prochlorperazine is more effective than the opioid hydromorphone in treating emergency room patients with acute migraine, a new study reports.

Acute migraine -- an intense, throbbing headache that may be accompanied by visual disturbances and sensitivity to light and sound -- is a disabling condition that results in 1.2 million visits to U.S. emergency rooms each year.

The opioid painkiller "hydromorphone is given in about 25 percent of all emergency department visits for acute migraine. However, it's well known that the use of prescription opioids can lead to serious risks of addiction, abuse and overdose and adversely impact treatment of migraine," said Dr. Peter Goadsby, chairman of the American Headache Society's Scientific Program Committee.

The new study was led by Dr. Benjamin Friedman of Albert Einstein College of Medicine in New York City. The evaluation included 126 patients with acute migraine treated at two New York City emergency departments. They received either prochlorperazine (Compro) plus diphenhydramine (Benadryl), or hydromorphone (Dilaudid).

Patients were assessed for sustained headache relief. That was defined as a reduction in severity to either mild or no headache within two hours of treatment, and maintaining that level for 48 hours after one dose of medication.

Sixty percent of patients who took prochlorperazine had sustained relief, compared to 31 percent in the hydromorphone group. The study was stopped early because the difference was so large.

"This study is important in providing clear evidence that hydromorphone is significantly less effective than prochlorperazine in achieving and maintaining headache relief," Goadsby said in a society news release.

The new findings support society treatment recommendations for adults who seek emergency care for acute migraine, he said.

"Physicians should first offer these patients intravenous prochlorperazine, metoclopramide, or subcutaneous sumatriptan, but not morphine or hydromorphone because of a lack of evidence for efficacy and concerns about side effects," Goadsby said.

The findings were presented recently at the annual meeting of the American Headache Society, in Boston. Research presented at medical meetings is typically considered preliminary because it is not subject to the same scrutiny as that of peer-reviewed journals.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on migraine.